NASDAQALVO

Carl Lokko Alvotech (NASDAQ:ALVO) said a confirmatory study for its biosimilar candidate AVT03 met its primary endpoint of demonstrating clinical similarity to Amgen’s (AMGN) osteoporosis drug Prolia. The Icelandic company said the study demonstrated similarity of AVT03 to Prolia, also known as denosumab, in terms of efficacy, safety, immunogenicity andContinue Reading